Developer docs
API playgroundTry for free, no card

Search company profiles

Aclairo Pharmaceutical Development Group

Full company profile

uuid000ibi6

Namestring
Aclairo Pharmaceutical Development Group
Legal namestring
Aclairo Pharmaceutical Development Group, Inc.
Websiteurl
aclairo.com
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSterling, United States
HQ citystring
Sterling
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical consulting services, nonclinical drug development, clinical pharmacology advisory, regulatory writing services, toxicology consulting
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Consulting Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Consulting Services
TypeProfessional Services
Description

Professional consulting fees for nonclinical development strategy, toxicology, DMPK/TK, clinical pharmacology, cell and gene therapy, and regulatory writing services. Revenue generated through service engagements with pharmaceutical and biotech companies.

aclairo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aclairo provides expert consulting services for nonclinical drug development and clinical pharmacology for human therapeutics. The firm delivers eight integrated service areas spanning cell and gene therapy, clinical pharmacology, DMPK/TK, drug development operations, drug development strategy, nonclinical pharmacology, scientific and regulatory writing, and toxicology. Engagements are tailored to pharmaceutical and biotech clients ranging from early-stage companies to large multinationals, covering everything from IND-enabling studies through regulatory submissions to FDA and global health authorities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aclairo Pharmaceutical Development Group offers a unified portfolio of expert consulting services for nonclinical drug development and clinical pharmacology. The core offering consists of eight integrated service areas: Cell and Gene Therapy Consulting (CGT modalities including AAV, lentivirus, gene editing, and cell therapies), Clinical Pharmacology Consulting (PK/PD, dose selection, regulatory submissions), Nonclinical DMPK/TK Services (ADME, bioanalytical methods, human dose projections), Nonclinical Drug Development Operations (CRO oversight, study monitoring, project management), Nonclinical Drug Development Strategy Consulting (regulatory strategy, gap analysis, program planning), Nonclinical Pharmacology Consulting (on/off-target effects, safety pharmacology), Scientific and Regulatory Writing Services (submission-ready documents for FDA and global health authorities), and Toxicology Consulting (safety pharmacology, genetic toxicology, general toxicology, carcinogenicity). These services are designed to work together, enabling clients to progress therapeutics from early development through IND-enabling studies to regulatory submissions and market approval. The company was founded in 2004 by ex-FDA regulators and has over 350 years of combined drug development experience.

Product and service8 records
1Cell and Gene Therapy Consulting
CategoryPharmaceutical Consulting - Cell and Gene Therapy
Description

Strategic advice, program support, and regulatory writing for cell and gene therapy modalities including AAV, lentivirus, LNP-delivered nucleic acids, in vivo and ex vivo gene editing, and cell therapies. Supports nonclinical strategy, regulatory planning, study design, and data interpretation for viral and non-viral delivery systems serving organizations developing human therapeutics.

2Clinical Pharmacology Consulting
CategoryPharmaceutical Consulting - Clinical Pharmacology
Description

Guidance, analysis, and reporting integrating pharmacokinetic, pharmacodynamic, dose selection, exposure response, drug interaction, and special population assessments to guide safe and effective drug use. Supports regulatory submissions including pIND, IND, NDA, CTD, BLA, and 510k for pharmaceutical and biotech clients developing human therapeutics.

3Nonclinical DMPK/TK Services
CategoryPharmaceutical Consulting - DMPK/TK
Description

ADME insights and guidance supporting program advancement, including pharmacokinetic analysis, toxicokinetics, bioanalytical method development, human dose projections using allometric scaling, MABEL, and IVIVE approaches, and exposure margin calculations. Designed for organizations developing human therapeutics requiring nonclinical drug metabolism and pharmacokinetic expertise.

4Nonclinical Drug Development Operations
CategoryPharmaceutical Consulting - Drug Development Operations
Description

Operational support including study monitors, CRO oversight, day-to-day communication with contract research organizations, on-site toxicology study monitoring, protocol development, data review, and report finalization activities for pharmaceutical and biotech clients running nonclinical drug development programs.

5Nonclinical Drug Development Strategy Consulting
CategoryPharmaceutical Consulting - Strategy
Description

Development of comprehensive nonclinical strategies tailored to specific programs, indications, and regulatory pathways. Includes program assessment, gap analysis, strategic planning, and ongoing support through study execution and regulatory interactions for organizations developing human therapeutics.

6Nonclinical Pharmacology Consulting
CategoryPharmaceutical Consulting - Nonclinical Pharmacology
Description

Expert guidance to characterize on- and off-target effects of drug products and meet regulatory expectations. Supports dose selection, species justification, special patient populations, and identification of potential off-target toxicities across small molecules, biologics, and cell/gene therapies for pharmaceutical and biotech clients.

7Scientific and Regulatory Writing Services
CategoryPharmaceutical Consulting - Regulatory Writing
Description

Preparation of high-quality, submission-ready documents for regulatory interactions and scientific communication. Supports INDs, CTAs, BLAs, NDAs, Investigator Brochures, pharmacology reports, DMPK reports, FDA meeting packages, and primary research manuscripts. Documents are developed in alignment with FDA and global health authority guidances for organizations developing human therapeutics.

8Toxicology Consulting
CategoryPharmaceutical Consulting - Toxicology
Description

Expert toxicology services spanning safety pharmacology, phototoxicity, genetic toxicology, general toxicology, carcinogenicity, developmental and reproductive toxicology, and juvenile toxicology. Supports strategy development, study design, conduct, interpretation, and regulatory submissions for global success for organizations developing human therapeutics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Aclairo is a wholly owned subsidiary of Experimental Pathology Laboratories, a private, employee-owned company. This acquisition in 2018 allows Aclairo consultants access to all of EPL's specialized pathology services and provides EPL clients with strategic advice from Aclairo.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty clinical pharmacology and pharmacokinetic consulting firm serving pharma and biotech with drug development strategy, modeling, and regulatory support — directly comparable services, target clients, and boutique scale as Aclairo.

TypeDirect peer
Description

Regulatory and scientific consulting firm staffed heavily by former FDA reviewers providing CMC, nonclinical, and clinical consulting to biologics developers — closely mirrors Aclairo's FDA-veteran model and regulatory advisory offering.

TypeDirect peer
Description

Biopharma consulting firm offering regulatory strategy, quality, clinical operations, and drug development advisory to pharma and biotech sponsors — overlaps with Aclairo's regulatory strategy and nonclinical development consulting services.

TypeBroad incumbent
Description

Full-service regulatory, compliance, and scientific consulting firm serving pharma across the product lifecycle — broader portfolio than Aclairo but adjacent specialty consulting for regulatory and drug development work.

TypeDirect peer
Description

Regulatory strategy and communications consultancy helping sponsors prepare for and navigate FDA interactions including INDs and advisory committees — directly comparable regulatory advisory positioning to Aclairo's regulatory writing and FDA-interaction services.

TypeBroad incumbent
Description

Large global CRO offering extensive nonclinical drug development, safety assessment, toxicology, and DMPK services across small molecules and biologics — a much broader incumbent that overlaps with Aclairo's nonclinical safety and DMPK consulting core.

TypeBroad incumbent
Description

Global CRO and life sciences services firm providing clinical, regulatory, and drug development consulting across the full development pipeline — broader incumbent with regulatory and clinical pharmacology advisory offerings that overlap with Aclairo's scope.

TypeBroad incumbent
Description

Large CRO providing nonclinical, clinical pharmacology, and regulatory services to pharma and biotech — directly overlapping preclinical, clinical pharmacology, and regulatory writing capabilities at much larger scale.

TypeBroad incumbent
Description

Global CRO with deep regulatory and clinical development consulting services including nonclinical strategy — broader portfolio with overlapping regulatory and drug development advisory offerings to the same pharma/biotech client base.

TypeBroad incumbent
Description

Mid-to-large CRO providing clinical pharmacology, regulatory affairs, and drug development consulting services to pharma and biotech — overlapping client base and adjacent nonclinical-to-clinical advisory capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aclairo Pharmaceutical Development Group

Pharmaceutical Consulting Servicesaclairo.com

Aclairo Pharmaceutical Development Group firmographics

Firmographics
Name
Aclairo Pharmaceutical Development Group
Legal name
Aclairo Pharmaceutical Development Group, Inc.
Website
https://aclairo.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Aclairo Pharmaceutical Development Group industry classification

Industry
Product category
Pharmaceutical Consulting Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical consulting services
  • Nonclinical drug development
  • Clinical pharmacology advisory
  • Regulatory writing services
  • Toxicology consulting

Where Aclairo Pharmaceutical Development Group is headquartered

Location

Headquarters

HQ city
Sterling
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aclairo Pharmaceutical Development Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Consulting Services: Professional consulting fees for nonclinical development strategy, toxicology, DMPK/TK, clinical pharmacology, cell and gene therapy, and regulatory writing services. Revenue generated through service engagements with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aclairo Pharmaceutical Development Group product offering

Product offering

Core offering

Aclairo provides expert consulting services for nonclinical drug development and clinical pharmacology for human therapeutics. The firm delivers eight integrated service areas spanning cell and gene therapy, clinical pharmacology, DMPK/TK, drug development operations, drug development strategy, nonclinical pharmacology, scientific and regulatory writing, and toxicology. Engagements are tailored to pharmaceutical and biotech clients ranging from early-stage companies to large multinationals, covering everything from IND-enabling studies through regulatory submissions to FDA and global health authorities.

Product overview

Aclairo Pharmaceutical Development Group offers a unified portfolio of expert consulting services for nonclinical drug development and clinical pharmacology. The core offering consists of eight integrated service areas: Cell and Gene Therapy Consulting (CGT modalities including AAV, lentivirus, gene editing, and cell therapies), Clinical Pharmacology Consulting (PK/PD, dose selection, regulatory submissions), Nonclinical DMPK/TK Services (ADME, bioanalytical methods, human dose projections), Nonclinical Drug Development Operations (CRO oversight, study monitoring, project management), Nonclinical Drug Development Strategy Consulting (regulatory strategy, gap analysis, program planning), Nonclinical Pharmacology Consulting (on/off-target effects, safety pharmacology), Scientific and Regulatory Writing Services (submission-ready documents for FDA and global health authorities), and Toxicology Consulting (safety pharmacology, genetic toxicology, general toxicology, carcinogenicity). These services are designed to work together, enabling clients to progress therapeutics from early development through IND-enabling studies to regulatory submissions and market approval. The company was founded in 2004 by ex-FDA regulators and has over 350 years of combined drug development experience.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell and Gene Therapy Consulting Strategic advice, program support, and regulatory writing for cell and gene therapy modalities including AAV, lentivirus, LNP-delivered nucleic acids, in vivo and ex vivo gene editing, and cell therapies. Supports nonclinical strategy, regulatory planning, study design, and data interpretation for viral and non-viral delivery systems serving organizations developing human therapeutics.
  • Clinical Pharmacology Consulting Guidance, analysis, and reporting integrating pharmacokinetic, pharmacodynamic, dose selection, exposure response, drug interaction, and special population assessments to guide safe and effective drug use. Supports regulatory submissions including pIND, IND, NDA, CTD, BLA, and 510k for pharmaceutical and biotech clients developing human therapeutics.
  • Nonclinical DMPK/TK Services ADME insights and guidance supporting program advancement, including pharmacokinetic analysis, toxicokinetics, bioanalytical method development, human dose projections using allometric scaling, MABEL, and IVIVE approaches, and exposure margin calculations. Designed for organizations developing human therapeutics requiring nonclinical drug metabolism and pharmacokinetic expertise.
  • Nonclinical Drug Development Operations Operational support including study monitors, CRO oversight, day-to-day communication with contract research organizations, on-site toxicology study monitoring, protocol development, data review, and report finalization activities for pharmaceutical and biotech clients running nonclinical drug development programs.
  • Nonclinical Drug Development Strategy Consulting Development of comprehensive nonclinical strategies tailored to specific programs, indications, and regulatory pathways. Includes program assessment, gap analysis, strategic planning, and ongoing support through study execution and regulatory interactions for organizations developing human therapeutics.
  • Nonclinical Pharmacology Consulting Expert guidance to characterize on- and off-target effects of drug products and meet regulatory expectations. Supports dose selection, species justification, special patient populations, and identification of potential off-target toxicities across small molecules, biologics, and cell/gene therapies for pharmaceutical and biotech clients.
  • Scientific and Regulatory Writing Services Preparation of high-quality, submission-ready documents for regulatory interactions and scientific communication. Supports INDs, CTAs, BLAs, NDAs, Investigator Brochures, pharmacology reports, DMPK reports, FDA meeting packages, and primary research manuscripts. Documents are developed in alignment with FDA and global health authority guidances for organizations developing human therapeutics.
  • Toxicology Consulting Expert toxicology services spanning safety pharmacology, phototoxicity, genetic toxicology, general toxicology, carcinogenicity, developmental and reproductive toxicology, and juvenile toxicology. Supports strategy development, study design, conduct, interpretation, and regulatory submissions for global success for organizations developing human therapeutics.

Companies that use Aclairo Pharmaceutical Development Group

Customer profile

Segments4 records

Ideal customer profiles2 records

Aclairo Pharmaceutical Development Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aclairo Pharmaceutical Development Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Experimental Pathology Laboratories (EPL)coreStrategic or Co-development Partner · 1 January 2018Aclairo is a wholly owned subsidiary of Experimental Pathology Laboratories, a private, employee-owned company. This acquisition in 2018 allows Aclairo consultants access to all of EPL's specialized pathology services and provides EPL clients with strategic advice from Aclairo.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Aclairo Pharmaceutical Development Group competitors and assessment

Company assessment

Direct peers

  • Nuventra Pharma Sciences: Specialty clinical pharmacology and pharmacokinetic consulting firm serving pharma and biotech with drug development strategy, modeling, and regulatory support — directly comparable services, target clients, and boutique scale as Aclairo.
  • Biologics Consulting Group: Regulatory and scientific consulting firm staffed heavily by former FDA reviewers providing CMC, nonclinical, and clinical consulting to biologics developers — closely mirrors Aclairo's FDA-veteran model and regulatory advisory offering.
  • Halloran Consulting Group: Biopharma consulting firm offering regulatory strategy, quality, clinical operations, and drug development advisory to pharma and biotech sponsors — overlaps with Aclairo's regulatory strategy and nonclinical development consulting services.
  • PharmApprove: Regulatory strategy and communications consultancy helping sponsors prepare for and navigate FDA interactions including INDs and advisory committees — directly comparable regulatory advisory positioning to Aclairo's regulatory writing and FDA-interaction services.

Broad incumbents

  • ProPharma Group: Full-service regulatory, compliance, and scientific consulting firm serving pharma across the product lifecycle — broader portfolio than Aclairo but adjacent specialty consulting for regulatory and drug development work.
  • Charles River Laboratories: Large global CRO offering extensive nonclinical drug development, safety assessment, toxicology, and DMPK services across small molecules and biologics — a much broader incumbent that overlaps with Aclairo's nonclinical safety and DMPK consulting core.
  • IQVIA: Global CRO and life sciences services firm providing clinical, regulatory, and drug development consulting across the full development pipeline — broader incumbent with regulatory and clinical pharmacology advisory offerings that overlap with Aclairo's scope.
  • Labcorp Drug Development (Fortrea): Large CRO providing nonclinical, clinical pharmacology, and regulatory services to pharma and biotech — directly overlapping preclinical, clinical pharmacology, and regulatory writing capabilities at much larger scale.
  • Parexel International: Global CRO with deep regulatory and clinical development consulting services including nonclinical strategy — broader portfolio with overlapping regulatory and drug development advisory offerings to the same pharma/biotech client base.
  • Worldwide Clinical Trials: Mid-to-large CRO providing clinical pharmacology, regulatory affairs, and drug development consulting services to pharma and biotech — overlapping client base and adjacent nonclinical-to-clinical advisory capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aclairo Pharmaceutical Development Group social profiles

Digital presence

Aclairo Pharmaceutical Development Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aclairo Pharmaceutical Development Group leadership team

Management profile

Number of profiles

Profiles16 records

Aclairo Pharmaceutical Development Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aclairo Pharmaceutical Development Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aclairo Pharmaceutical Development Group

What does Aclairo Pharmaceutical Development Group do?

Aclairo provides expert consulting services for nonclinical drug development and clinical pharmacology for human therapeutics. The firm delivers eight integrated service areas spanning cell and gene therapy, clinical pharmacology, DMPK/TK, drug development operations, drug development strategy, nonclinical pharmacology, scientific and regulatory writing, and toxicology. Engagements are tailored to pharmaceutical and biotech clients ranging from early-stage companies to large multinationals, covering everything from IND-enabling studies through regulatory submissions to FDA and global health authorities.

Is Aclairo Pharmaceutical Development Group a public or private company?

Aclairo Pharmaceutical Development Group is a private company. It is classified as corporate owned and is currently operating.

When was Aclairo Pharmaceutical Development Group founded?

Aclairo Pharmaceutical Development Group was founded in 2004. It employs 11 to 50 people.

Where is Aclairo Pharmaceutical Development Group based?

Aclairo Pharmaceutical Development Group is headquartered in Sterling, United States, in the North America region.

How does Aclairo Pharmaceutical Development Group make money?

One revenue line is on record: consulting Services.

Who are Aclairo Pharmaceutical Development Group's main competitors?

Direct peers on record are Nuventra Pharma Sciences, Biologics Consulting Group, Halloran Consulting Group and PharmApprove. Broad incumbents are ProPharma Group, Charles River Laboratories, IQVIA, Labcorp Drug Development (Fortrea), Parexel International and Worldwide Clinical Trials.

Does Aclairo Pharmaceutical Development Group have an API?

No public API is recorded for Aclairo Pharmaceutical Development Group.

What industry is Aclairo Pharmaceutical Development Group in?

Aclairo Pharmaceutical Development Group's product category is Pharmaceutical Consulting Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales